ITOS
Income statement / Annual
Last year (2023), iTeos Therapeutics, Inc.'s total revenue was $12.60 M,
a decrease of 95.29% from the previous year.
In 2023, iTeos Therapeutics, Inc.'s net income was -$112.64 M.
See iTeos Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$12.60 M
|
$267.63 M
|
$344.78 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$898,000.00 |
$813,000.00 |
$615,000.00 |
$535,000.00 |
$611,000.00 |
$505,000.00 |
| Gross Profit |
$11.70 M |
$266.82 M |
$344.16 M |
-$535,000.00 |
-$611,000.00 |
-$505,000.00 |
| Gross Profit Ratio |
0.93 |
1 |
1 |
0 |
0 |
0 |
| Research and Development
Expenses |
$113.30 M
|
$97.36 M
|
$59.37 M
|
$29.90 M
|
$19.21 M
|
$17.19 M
|
| General & Administrative
Expenses |
$50.40 M
|
$43.95 M
|
$40.51 M
|
$15.34 M
|
$8.84 M
|
$4.31 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$50.40 M
|
$43.95 M
|
$40.51 M
|
$15.34 M
|
$8.84 M
|
$4.31 M
|
| Other Expenses |
$0.00 |
-$3.26 M |
-$10.18 M |
-$5.93 M |
-$4.78 M |
-$163,000.00 |
| Operating Expenses |
$163.70 M |
$138.04 M |
$89.69 M |
$39.31 M |
$23.27 M |
$17.82 M |
| Cost And Expenses |
$163.70 M |
$138.04 M |
$89.69 M |
$39.31 M |
$23.27 M |
$17.82 M |
| Interest Income |
$31.77 M |
$11.36 M |
$78,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$66,000.00 |
| Depreciation &
Amortization |
$898,000.00
|
$813,000.00
|
$615,000.00
|
$535,000.00
|
$611,000.00
|
$505,000.00
|
| EBITDA |
-$151.10 M
|
$148.38 M
|
$257.08 M
|
-$37.84 M
|
-$21.72 M
|
-$17.48 M
|
| EBITDA Ratio |
-12 |
0.49 |
0.74 |
0 |
0 |
0 |
| Operating Income Ratio
|
-12
|
0.47
|
0.71
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$42.07 M
|
$22.41 M
|
$11.56 M
|
$7.15 M
|
$5.71 M
|
$3.46 M
|
| Income Before Tax |
-$109.03 M |
$148.74 M |
$256.46 M |
-$38.09 M |
-$22.34 M |
-$18.05 M |
| Income Before Tax Ratio
|
-8.66
|
0.56
|
0.74
|
0
|
0
|
0
|
| Income Tax Expense |
$3.61 M |
$52.08 M |
$41.94 M |
-$57,000.00 |
$119,000.00 |
$11,000.00 |
| Net Income |
-$112.64 M |
$96.65 M |
$214.52 M |
-$38.03 M |
-$22.45 M |
-$18.06 M |
| Net Income Ratio |
-8.94 |
0.36 |
0.62 |
0 |
0 |
0 |
| EPS |
-3.15 |
2.72 |
6.1 |
-1.09 |
-0.64 |
-2.4 |
| EPS Diluted |
-3.15 |
2.56 |
5.68 |
-1.09 |
-0.64 |
-2.4 |
| Weighted Average Shares
Out |
$35.76 M
|
$35.55 M
|
$35.18 M
|
$35.04 M
|
$35.02 M
|
$7.51 M
|
| Weighted Average Shares
Out Diluted |
$35.76 M
|
$37.77 M
|
$37.77 M
|
$35.04 M
|
$35.02 M
|
$7.51 M
|
| Link |
|
|
|
|
|
|
